Canagliflozin Increases Postprandial Total Glucagon-Like Peptide 1 Levels in the Absence of α-Glucosidase Inhibitor Therapy in Patients with Type 2 Diabetes: A Single-Arm, Non-randomized, Open-Label Study
Sign Up to like & getrecommendations! Published in 2019 at "Diabetes Therapy"
DOI: 10.1007/s13300-019-00689-w
Abstract: To investigate canagliflozin-induced changes in postprandial total glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) levels in patients with type 2 diabetes mellitus (T2DM). Forty-five patients with T2DM who had inadequate glycemic control (glycated… read more here.
Keywords: postprandial total; glp; gip; glucosidase inhibitor ... See more keywords